Home › Mantle Cell Lymphoma › Minnesota
Pag-aaral pangklinika para sa Mantle Cell Lymphoma sa Minnesota
14 pag-aaral para sa Mantle Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Minnesota.
Mga Lungsod sa Minnesota
Opisyal na teksto ng pag-aaral (English)
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- University of Minnesota, Minneapolis
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT05370430A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT03125642Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- at 14 pa
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05976763A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Mayo Clinic Rochester, Rochester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06742996Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06533579A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Rochester
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06542250DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Nagre-recruitPhase 2
Hanggang edad 60 · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT03314974Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Peb 27, 2026 · NCT06151730BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 20, 2026 · NCT06854003SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Mayo Clinic in Rochester, Rochester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 18, 2024 · NCT05910801Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.